Among top hits, which preferentially impaired the viability of “persister” cells while sparing the naïve population, they identified BRD4. Consistent with this model, “persister” cells were more sensitive to BRD4 inhibition in vitro, and combination therapy with GSI and JQ1 in a GSI “naïve” T-ALL xenotransplant model was more effective than either drug alone (59). Here, BRD4 is linked to acute lymphoblastic leukemia.